Use este identificador para citar ou linkar para este item: http://sgc.anlis.gob.ar/handle/123456789/2220
Título: Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs
Autor(es): Kurbatova, E V 
Cavanaugh, J S 
Shah, N S 
Wright, A. 
Kim, HeeJin 
Metchock, B 
Van Deun, A. 
Barrera, Lucía 
Boulahbal, F 
Richter, E 
Martín-Casabona, N 
Arias, F 
Zemanova, I 
Drobniewski, F 
Santos Silva, A 
Coulter, C 
Lumb, R 
Cegielski, J P 
Palavras-chave: Mycobacterium tuberculosis;Tuberculosis;Resistencia a Medicamentos
Data do documento: 2012
Editora: International Union Against Tuberculosis and Lung Disease
Jornal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 
Resumo: 
Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistance-associated DNA mutations.
Descrição: 
Fil: Kurbatova, E V. Centers for Disease Control and Prevention, Atlanta, Georgia; Estados Unidos.

Fil: Cavanaugh, J S. Centers for Disease Control and Prevention, Atlanta, Georgia; Estados Unidos.

Fil: Shah, N S. Division of General Internal Medicine, Albert Einstein College of Medicine, Bronx, New York; Estados Unidos.

Fil: Wright, A. World Health Organization, Geneva; Suiza.

Fil: Kim, HeeJin. Korean Institute of Tuberculosis, Seoul; Korea.

Fil: Metchock, B. Centers for Disease Control and Prevention, Atlanta, Georgia; Estados Unidos.

Fil: Van Deun, A. Institute of Tropical Medicine, Antwerp; Belgica.

Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.

Fil: Boulahbal, F. Institut Pasteur d’Algérie, Alger; Argelia.

Fil: Richter, E. National Reference Center for Mycobacteria, Borstel; Alemania.

Fil: Martín-Casabona, N. Hospital Universitaris Vall d’Hebron, Barcelona; España.

Fil: Arias, F. Institute of Public Health of Chile, Providencia Santiago, Santiago; Chile.

Fil: Zemanova, I. National Institute of Public Health, Scrobarova; Chequia.

Fil: Drobniewski, F. Health Protection Agency, London; Reino Unido.

Fil: Santos Silva, A. National Institute of Health, Porto; Portugal.

Fil: Coulter, C. Queensland Mycobacterium Reference Laboratory, Brisbane, Queensland; Australia.

Fil: Lumb, R. Institute of Medical and Veterinary Science, Adelaide, South Australia; Australia.

Fil: Cegielski, J P. Centers for Disease Control and Prevention, Atlanta, Georgia; Estados Unidos.
URI: http://sgc.anlis.gob.ar/handle/123456789/2220
ISSN: 1815-7920
DOI: 10.5588/ijtld.11.0542
Direitos: Closed Access
Aparece nas Coleções:Publicaciones INEI

Arquivos neste item:
Arquivo Descrição TamanhoFormato
10.5588_ijtld.11.0542.pdfArtículo en inglés120.9 kBAdobe PDFVer/Aberto
Mostrar registro completo do item

Visualização de página

76
Checado em 16/06/2025

Download(s)

11
Checado em 16/06/2025

Google ScholarTM

Checar

Altmetric

Altmetric


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.